Antiandrogens may increase mortality risk in men with CVD
August 30, 2019
Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.
Badar M. Mian, MD
Untreated MIBC has short natural course, significant morbidity
August 21, 2019
"There appears to be a strikingly high likelihood of increased morbidity and poor outcomes in patient who are not receiving definitive therapy," writes Badar M. Mian, MD.
Renal mass biopsy safe, but when is it necessary?
July 23, 2019
"While the safety and feasibility of the renal mass biopsy procedure has been established, if or when to obtain the biopsy remains a topic for active discussion," writes Badar M. Mian, MD.
PSA adjustments are required in men taking 5-ARIs
July 3, 2019
"This report brings to light an often-suspected but previously undocumented clinical issue in great and alarming detail," says Badar M. Mian, MD.
PCa study evaluates ‘clinically meaningful’ margins, recurrence
May 27, 2019
"In this study, even if only the higher risk subgroup (unfavorable PSMs and advanced stage/grade) were to receive adjuvant treatment, nearly 75% of patients may potentially be overtreated," writes Badar M. Mian, MD.
New ERSPC data reveal benefits of repeated PSA screening
May 16, 2019
"Despite improvements in the diagnostic markers and imaging, overdiagnosis and particularly overtreatment continue to pose a challenge for the urologic community," writes Badar M. Mian, MD.
ADT’s benefit studied in post-RP men undergoing salvage RT
March 10, 2019
"Biochemical recurrence after radical prostatectomy may occur in 20% to 50% of cases and salvage radiation therapy is considered the best treatment in most cases. But the questions about whether to add androgen deprivation therapy, as well as its dose and duration, remain subjects of active clinical debate," writes Badar M. Mian, MD.
High-risk prostate Ca: New study sheds light on RP vs. RT
February 28, 2019
Surgery was associated with improved cancer-specific and overall mortality compared with radiation therapy, according to a recent study.
Many low-risk PCa patients on AS may be lost to follow-up
January 14, 2019
"This study highlights the need for each practice to perform a self-audit of its AS protocol and take all necessary measures to ensure that patients are not lost during the monitoring period," writes Badar M. Mian, MD.
Should radiotherapy be offered for metastatic prostate Ca?
November 20, 2018
Phase III data indicate benefit only for a subset of patients.
